GeoVax to Attend BIO International Convention June 18-21 in Boston
JUN 11, 2012 - 09:00 ET
FOR: GEOVAX LABS, INC.
Exhibiting at Booth 1035 in Georgia Pavilion
ATLANTA, GA--(Marketwire - June 11, 2012) - GeoVax Labs, Inc. (
GeoVax's President and CEO, Dr. Robert McNally, Board Chairman, David Dodd, and colleagues will be available to meet with interested parties either within the Georgia Pavilion or through the BIO partnering system to discuss the Company's preventive and therapeutic HIV/AIDS vaccine programs. In addition, Company executives anticipate meetings with the third party manufacturers of GeoVax's vaccines; with its contacts at analytical laboratories with which it is currently working; and with some of the Company's research partners.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. For more information, please visit www.bio.org.
GeoVax Labs, Inc. is a biotechnology company developing human vaccines for HIV (Human Immunodeficiency Virus - that leads to AIDS). GeoVax's HIV/AIDS vaccine technology is exclusively licensed from Emory University in Atlanta, GA, and is the subject of more than 20 issued or filed patent applications. GeoVax vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected. GeoVax vaccines are also being tested as a therapeutic treatment (for people already infected with the HIV-1 virus).
GeoVax's core vaccine technologies were developed by Dr. Harriet Robinson, Chief Scientific Officer, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC) and GeoVax. The technology uses recombinant DNA to prime the immune response and recombinant modified vaccinia Ankara (MVA) to boost the primed response. Both the DNA vaccine and the MVA vaccine express non-infectious virus-like-particles displaying the natural trimeric form of the HIV envelope protein.
GeoVax's vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. These trials have tested various combinations and doses of the DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported Phase 2 testing in an ongoing, fully enrolled, 299 participant trial in North and South America. The vaccine is also undergoing Phase 1/2 testing as a therapeutic in HIV-infected individuals.
At The Investor Relations Group: